Back to Search
Start Over
Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data
- Source :
- Vaccine
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- This is a Brighton Collaboration Case Definition of the term "Acute Respiratory Distress Syndrome - ARDS" to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission. The comments of the reviewers were taken into consideration and edits incorporated in this final manuscript.
- Subjects :
- Adverse event
Adult
ARDS
COVID-19 Vaccines
Case definition
media_common.quotation_subject
030231 tropical medicine
Context (language use)
Review
Acute respiratory distress
Guidelines
03 medical and health sciences
Presentation
0302 clinical medicine
Humans
Medicine
030212 general & internal medicine
Adverse effect
media_common
Pediatric
Respiratory Distress Syndrome
Data collection
Acute respiratory distress syndrome
General Veterinary
General Immunology and Microbiology
SARS-CoV-2
business.industry
Data Collection
Public Health, Environmental and Occupational Health
COVID-19
medicine.disease
Infectious Diseases
Immunization
Preparedness
Molecular Medicine
Medical emergency
business
Subjects
Details
- ISSN :
- 0264410X
- Volume :
- 39
- Database :
- OpenAIRE
- Journal :
- Vaccine
- Accession number :
- edsair.doi.dedup.....eee83dafc6a46975691f92356fb25854
- Full Text :
- https://doi.org/10.1016/j.vaccine.2021.01.053